数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 首席执行官兼董事、临时首席财务官 -- 1.79万(USD) 850.00 2020-07-08
郑军 董事 -- 未披露 未持股 2020-07-08
李俊松 独立董事 -- 未披露 未持股 2020-07-08
陆兔林 独立董事 -- 未披露 未持股 2020-07-08
范文伟 独立董事 -- 未披露 未持股 2020-07-08

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
周峰 首席执行官兼董事、临时首席财务官 -- 1.79万(USD) 850.00 2020-07-08
邓京振 首席科学官和首席运营官 -- 2.68万(USD) 未持股 2020-07-08

董事简历

中英对照 |  中文 |  英文
周峰

周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。


Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。
Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
郑军

郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。


Jun Zheng has been appointed as our director on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor’s degree from Jiangnan University Wuxi Light Industry University in 1999.
郑军于2018年12月31日被任命为公司董事。郑先生从1999年至2004年曾任江西博世达制药有限公司销售区域经理,以及台州九天药业有限公司部门经理和副总经理。郑先生于2005年至2012年间担任总经理。郑先生于2013年至2015年间担任台州仁济中药饮片有限公司总经理,并于2016年起担任江苏健康药业投资管理有限公司总经理。 到2017年。郑先生现为台州素悬堂副总裁。 郑先生于1999年在江南大学无锡轻工业大学获得学士学位。
Jun Zheng has been appointed as our director on December 31 2018. Mr. Zheng was a sales area manager at Jiangxi Bo Shi Da Pharmaceutical Co., Ltd. from 1999 to 2004 and a department manager and deputy general manager at Taizhou Jiutian Pharmaceutical Co., Ltd. from the 2005 to 2012. Mr. Zheng served as a general manager at Taizhou Renji Chinese Traditional Medicine Pieces Co., Ltd. from 2013 to 2015 and a general manager at Jiangsu Health Pharmaceutical Investment Management Co., Ltd. from 2016 to 2017. Currently, Mr. Zheng is a vice president at Taizhou Suxuantang. Mr. Zheng received his bachelor’s degree from Jiangnan University Wuxi Light Industry University in 1999.
李俊松

李俊松在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。李先生在中医药行业有着20多年的丰富经验。自2009年,李先生担任南京中医药大学研究员,并于1986年至2003年,担任南京中医药大学副教授。李先生于1986年毕业于南京中医药大学,并获得中医药文学学士学位,2002年获得中医药硕士学位,2006年获得上海中医药大学博士学位。凭借其在中医领域有丰富的工作经验和教育背景,我们相信李先生有充分的资格作为董事会成员。


Junsong Li has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Li has over 20 year-experience in the TCM industry. Mr. Li has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003 Mr. Li worked as an associate professor of Nanjing TCM Hospital. Mr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. Mr. Li obtained his PhD from Shanghai TCM University in 2006.
李俊松在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。李先生在中医药行业有着20多年的丰富经验。自2009年,李先生担任南京中医药大学研究员,并于1986年至2003年,担任南京中医药大学副教授。李先生于1986年毕业于南京中医药大学,并获得中医药文学学士学位,2002年获得中医药硕士学位,2006年获得上海中医药大学博士学位。凭借其在中医领域有丰富的工作经验和教育背景,我们相信李先生有充分的资格作为董事会成员。
Junsong Li has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Li has over 20 year-experience in the TCM industry. Mr. Li has served as the researcher of Nanjing TCM University since 2009. From 1986 to 2003 Mr. Li worked as an associate professor of Nanjing TCM Hospital. Mr. Li graduated from Nanjing TCM University with a Bachelor of Arts in TCM in 1986 and a Master’s Degree in TCM in 2002. Mr. Li obtained his PhD from Shanghai TCM University in 2006.
陆兔林

陆兔林在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。陆先生现任南京中医药大学教授,是中医学界的资深人士。自2012年,陆先生担任国家教育部中医药加工联合实验室主任,并自2008年起,担任国家中医药管理局中药饮片标准实验室副主任,自2007年起,担任江苏省中医药加工重点实验室副主任,自2016年以来,担任南京中医药大学中药制剂系副主任。自2014年,陆先生担任中国中药饮片产品质量保证专业委员会常务副主任。陆先生分别于1989年,1999年和2003年,获得理学学士学位,理学硕士学位和理学博士学位。


Tulin Lu has been appointed as our independent director upon closing of our IPO on December 31 2018. Currently, Dr. Lu is a Professor at Nanjing University of TCM. As a veteran in the TCM academia, Dr. Lu has also served as the Chief Director at the co-laboratory of TCM Processing of Ministry of Education of the P. R. China since 2012 the Deputy Director of the standard laboratory of TCM pieces at the State Administration of TCM of the P. R. China since 2008 the Deputy Director at Jiangsu Provincial Key Laboratory of the Processing of TCM since 2007 the Deputy Director of the department of Processing preparation of TCM at Nanjing University of TCM since 2016 and the Executive Deputy Director of TCM Pieces Quality Assurance Specialized Committee of China since 2014. Dr. Lu received his Ph. D, Master of Science, and Bachelor of Science degrees from Nanjing University of TCM in 1989 1999 and 2003 respectively.
陆兔林在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。陆先生现任南京中医药大学教授,是中医学界的资深人士。自2012年,陆先生担任国家教育部中医药加工联合实验室主任,并自2008年起,担任国家中医药管理局中药饮片标准实验室副主任,自2007年起,担任江苏省中医药加工重点实验室副主任,自2016年以来,担任南京中医药大学中药制剂系副主任。自2014年,陆先生担任中国中药饮片产品质量保证专业委员会常务副主任。陆先生分别于1989年,1999年和2003年,获得理学学士学位,理学硕士学位和理学博士学位。
Tulin Lu has been appointed as our independent director upon closing of our IPO on December 31 2018. Currently, Dr. Lu is a Professor at Nanjing University of TCM. As a veteran in the TCM academia, Dr. Lu has also served as the Chief Director at the co-laboratory of TCM Processing of Ministry of Education of the P. R. China since 2012 the Deputy Director of the standard laboratory of TCM pieces at the State Administration of TCM of the P. R. China since 2008 the Deputy Director at Jiangsu Provincial Key Laboratory of the Processing of TCM since 2007 the Deputy Director of the department of Processing preparation of TCM at Nanjing University of TCM since 2016 and the Executive Deputy Director of TCM Pieces Quality Assurance Specialized Committee of China since 2014. Dr. Lu received his Ph. D, Master of Science, and Bachelor of Science degrees from Nanjing University of TCM in 1989 1999 and 2003 respectively.
范文伟

范文伟在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。范先生现任中国注册会计师事务所—北京华申会计师事务所合伙人,负责国际审计监督,包括对几家跨国公司中国子公司的财务报表进行审计。他的职业生涯始于2000年由普华永道收购的世永中和会计师事务所。范先生拥有注册会计师和注册税务师证书。范先生于1992年毕业于江苏财经大学,并获得学士学位。


Wenwei Fan has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterhouseCoopers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jiangsu University of Finance and Economics in 1992 with a bachelor’s degree.
范文伟在纳斯达克首次公开招股后,将担任中国苏轩堂药业有限公司独立董事。范先生现任中国注册会计师事务所—北京华申会计师事务所合伙人,负责国际审计监督,包括对几家跨国公司中国子公司的财务报表进行审计。他的职业生涯始于2000年由普华永道收购的世永中和会计师事务所。范先生拥有注册会计师和注册税务师证书。范先生于1992年毕业于江苏财经大学,并获得学士学位。
Wenwei Fan has been appointed as our independent director upon closing of our IPO on December 31 2018. Mr. Fan currently is a Partner of a Chinese Certified Public Accountant firm, Beijing Huashen Accounting Firm, where he is in charge of supervising international auditing, including auditing financial statements for Chinese subsidiaries of several multinational companies. He started his career with ShiyongZhonghe Accounting firm, which was acquired by PricewaterhouseCoopers in 2000. Mr. Fan is a Certified Public Accountant and Certified Tax Agent in China. He graduated from Jiangsu University of Finance and Economics in 1992 with a bachelor’s degree.

高管简历

中英对照 |  中文 |  英文
周峰

周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。


Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
周峰,自2017年7月4日起担任中国苏轩堂药业有限公司董事长兼首席执行官(CEO)。自2017年5月,周先生任可变利益实体—江苏苏轩堂药业有限公司首席执行官。2015年1月至2017年5月,周先生担任江苏苏轩堂药业有限公司副总经理。我们相信,周先生作为公司创始人,总裁,首席执行官以及我们最大的控股股东,凭借其独特的见解和丰富的经验理应成为我们董事会的一员。周先生毕业于中国人民解放军后勤工程学院,工商管理专业。
Feng Zhou has been our CEO and director since July 4 2017. He was the CEO of Taizhou Suxuantang, our VIE Entity from May 2017 to February, 2018. From January 2015 to May 2017 he was the vice manager of Taizhou Suxuantang. As vice manager of Taizhou Suxuantang, he was responsible for procurement and formulating a cost effective strategy for purchasing goods and services. Mr. Zhou graduated from Logistical Engineering University of PLA and majored in Business Administration.
邓京振

邓京振自2017年3月起担任中国苏轩堂药业有限公司首席科学官(CSO)和首席营运官(COO)。 自2013年6月,邓博士担任江苏苏轩堂药业有限公司副总经理和首席科学官(CSO),并重建公司的研发团队。邓博士在美国大学及药企有着16年的研究和工作经历,尤其在天然产物(中药)和新药研究领域,有着16年的丰富经验,曾担任美国弗吉尼亚大学博士后研究员和美国药物研发公司主管。邓博士在中国有着14年的工作经历,曾在中国药科大学和江西中药研发机构任职,并曾担任上海RCT医药有限公司首席执行官(CEO)。通过建立新药研发策略,运用现代科技创新技术和方法,持续不断地研发新型现代中药饮片产品,以满足公司更高的新产品及产品质量的要求。邓博士于1982年获得江西中医学院理学学士学位,并于1989年和1992年分别获得中国药科大学理学硕士学位和博士学位。


Jingzhen Deng has been our CSO since June 2013 our COO since March 2017 and CEO of Taizhou Suxuantang since February, 2018. He has been the vice president of Taizhou Suxuantang in June 2013 and rebuilt its R&D team. Dr. Deng has 16 years of experience at a university University of Virginia as a postdoctoral scientist and various pharmaceutical companies Pinnacle Pharmaceuticals, Inc. and Drumetix Laboratories, as directors of R&D specializing in natural products and new drug discovery in the USA, and more than 14 years at a Traditional Chinese Medicine “TCM” related university (China Pharmaceutical University), institute (Jiangxi Institute of TCM), and pharmaceutical company (RCT Pharmaceuticals, Inc. as CEO in Shanghai) in China. He established the general R&D strategy of using modern technology to revolutionize TCMP production, and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard at the company. Dr. Deng received his Bachelor of Science from Jiangxi University of Traditional Chinese Medicine in 1982 Master and Doctoral degrees from China Pharmaceutical University in 1989 and 1992 respectively.
邓京振自2017年3月起担任中国苏轩堂药业有限公司首席科学官(CSO)和首席营运官(COO)。 自2013年6月,邓博士担任江苏苏轩堂药业有限公司副总经理和首席科学官(CSO),并重建公司的研发团队。邓博士在美国大学及药企有着16年的研究和工作经历,尤其在天然产物(中药)和新药研究领域,有着16年的丰富经验,曾担任美国弗吉尼亚大学博士后研究员和美国药物研发公司主管。邓博士在中国有着14年的工作经历,曾在中国药科大学和江西中药研发机构任职,并曾担任上海RCT医药有限公司首席执行官(CEO)。通过建立新药研发策略,运用现代科技创新技术和方法,持续不断地研发新型现代中药饮片产品,以满足公司更高的新产品及产品质量的要求。邓博士于1982年获得江西中医学院理学学士学位,并于1989年和1992年分别获得中国药科大学理学硕士学位和博士学位。
Jingzhen Deng has been our CSO since June 2013 our COO since March 2017 and CEO of Taizhou Suxuantang since February, 2018. He has been the vice president of Taizhou Suxuantang in June 2013 and rebuilt its R&D team. Dr. Deng has 16 years of experience at a university University of Virginia as a postdoctoral scientist and various pharmaceutical companies Pinnacle Pharmaceuticals, Inc. and Drumetix Laboratories, as directors of R&D specializing in natural products and new drug discovery in the USA, and more than 14 years at a Traditional Chinese Medicine “TCM” related university (China Pharmaceutical University), institute (Jiangxi Institute of TCM), and pharmaceutical company (RCT Pharmaceuticals, Inc. as CEO in Shanghai) in China. He established the general R&D strategy of using modern technology to revolutionize TCMP production, and continue developing newly advanced and non-decocting TCMP/TCM products capable of meeting the highest quality standard at the company. Dr. Deng received his Bachelor of Science from Jiangxi University of Traditional Chinese Medicine in 1982 Master and Doctoral degrees from China Pharmaceutical University in 1989 and 1992 respectively.